Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ISA 2024 | The potential role of machine learning in amyloidosis

Shankara Anand • 28 May 2024
ISA 2024
Amyloidosis Rare Diseases

Shankara Anand, MD, MS, Boston University School of Medicine, Boston, MA, briefly discusses the potential value of implementing machine learning and artificial intelligence (AI) in the field of amyloidosis. This interview took place at the XIX International Symposium on Amyloidosis (ISA) in Rochester, MN.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

More from Shankara Anand

Machine learning-based clustering to improve risk stratification in newly diagnosed AL amyloidosis
2:32
Machine learning-based clustering to improve risk stratification in newly diagnosed AL amyloidosis
Shankara Anand • 28 May 2024
The future of next-generation sequencing assays in myeloma treatment
0:53
The future of next-generation sequencing assays in myeloma treatment
Shankara Anand • 12 Dec 2021
Genomic profiling of smoldering myeloma identifies high- and low- risk patients
2:20
Genomic profiling of smoldering myeloma identifies high- and low- risk patients
Shankara Anand • 12 Dec 2021

Related Videos

How may the timing of TP53 mutation acquisition impact outcomes in patients with MPNs?
2:21
How may the timing of TP53 mutation acquisition impact outcomes in patients with MPNs?
Akriti Jain • 27 May 2026
Tagraxofusp, hyper-CVAD, and venetoclax for patients with BPDCN: Phase II study results
1:40
Tagraxofusp, hyper-CVAD, and venetoclax for patients with BPDCN: Phase II study results
Naveen Pemmaraju • 30 May 2026
How the FDA approval of pivekimab sunirine may shape the field of BPDCN & advice for clinicians
2:20
How the FDA approval of pivekimab sunirine may shape the field of BPDCN & advice for clinicians
Naveen Pemmaraju • 29 May 2026
The importance of alloSCT in improving outcomes for patients with BPDCN
1:40
The importance of alloSCT in improving outcomes for patients with BPDCN
Naveen Pemmaraju • 29 May 2026
The content of VJHemOnc is intended for healthcare professionals